The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial (Q39275836)

10 September 2017

The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

10 September 2017

0 references

0 references

1 reference

non-alcoholic fatty liver

inferred from title

1 reference

1 reference

11

Hajime Sunagozaka

1 reference

10 September 2017

Yumie Takeshita

1

1 reference

10 September 2017

Toshinari Takamura

2

1 reference

10 September 2017

Masao Honda

3

1 reference

10 September 2017

Yuki Kita

4

1 reference

10 September 2017

Yoh Zen

5

1 reference

10 September 2017

Ken-ichiro Kato

6

1 reference

10 September 2017

Hirofumi Misu

7

1 reference

10 September 2017

Tsuguhito Ota

8

1 reference

10 September 2017

Mikiko Nakamura

9

1 reference

10 September 2017

Kazutoshi Yamada

10

1 reference

10 September 2017

Kuniaki Arai

12

1 reference

10 September 2017

Tatsuya Yamashita

13

1 reference

10 September 2017

Eishiro Mizukoshi

14

1 reference

10 September 2017

Shuichi Kaneko

15

1 reference

10 September 2017

language of work or name

1 reference

10 January 2014

1 reference

10 September 2017

1 reference

10 September 2017

57

1 reference

10 September 2017

5

1 reference

10 September 2017

878-890

1 reference

https://scigraph.springernature.com/pub.10.1007/s00125-013-3149-9

10 September 2017

0 references

cites work

Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Palmitate induces insulin resistance in H4IIEC3 hepatocytes through reactive oxygen species produced by mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Sterol regulatory element-binding factor 2 (SREBF-2) predicts 7-year NAFLD incidence and severity of liver disease and lipoprotein and glucose dysmetabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Lipoprotein metabolism mediates the association of MTP polymorphism with beta-cell dysfunction in healthy subjects and in nondiabetic normolipidemic patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

What is the best predictor of future type 2 diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Acute hyperinsulinemia reduces plasma concentrations of homocysteine in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Expression of sterol regulatory element-binding protein 1c (SREBP-1c) mRNA in rat hepatoma cells requires endogenous LXR ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Niemann-Pick C1-Like 1 deletion in mice prevents high-fat diet-induced fatty liver by reducing lipogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

A high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Insulin protects liver cells from saturated fatty acid-induced apoptosis via inhibition of c-Jun NH2 terminal kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

The coactivator PGC-1 is involved in the regulation of the liver carnitine palmitoyltransferase I gene expression by cAMP in combination with HNF4 alpha and cAMP-response element-binding protein (CREB)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Down-regulation of hepatic HNF4alpha gene expression during hyperinsulinemia via SREBPs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

MicroRNA modulation of cholesterol homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Selective binding of sterol regulatory element-binding protein isoforms and co-regulatory proteins to promoters for lipid metabolic genes in liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-3149-9

Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions

21 January 2018

1 reference

12 December 2020

Liver steatosis, but not fibrosis, is associated with insulin resistance in nonalcoholic fatty liver disease

1 reference

12 December 2020

Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis

1 reference

12 December 2020

Glucose clamp technique: a method for quantifying insulin secretion and resistance

1 reference

12 December 2020

10.1007/S00125-013-3149-9

Identifiers

DOI

1 reference

10 September 2017

1 reference